Evofem Biosciences, Inc.
EVFM · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | 471% | -88.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | 84.4% | 56.8% | 78.7% |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | – | -23.1% | 65.8% | -9% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | – | -37% | 113.1% | -42.8% |
| EPS Diluted | -0.01 | -0.015 | 0 | -0.032 |
| % Growth | 35.1% | -7,800% | 100.6% | – |
| Operating Cash Flow | $0 | -$0 | $0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | $0 | -$0 | $0 | -$0 |